Skip to Main content Skip to Navigation
Journal articles

Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.

Abstract : MRL/lpr mice develop a human lupuslike syndrome and, as in autoimmune lymphoproliferative syndrome (ALPS), massive lymphoproliferation due to inactivation of Fas-mediated apoptosis. Presently, no effective therapy exists for ALPS, and long term, therapies for lupus are hazardous. We show herein that arsenic trioxide (As(2)O(3)) is able to achieve quasi-total regression of antibody- and cell-mediated manifestations in MRL/lpr mice. As(2)O(3) activated caspases and eliminated the activated T lymphocytes responsible for lymphoproliferation and skin, lung, and kidney lesions, leading to significantly prolonged survival rates. This treatment also markedly reduced anti-DNA autoantibody, rheumatoid factor, IL-18, IFN-gamma, nitric oxide metabolite, TNF-alpha, Fas ligand, and IL-10 levels and immune-complex deposits in glomeruli. As(2)O(3) restored cellular reduced glutathione levels, thereby limiting the toxic effect of nitric oxide, which is overproduced in MRL/lpr mice. Furthermore, As(2)O(3) protected young animals against developing the syndrome and induced almost total disease disappearance in older affected mice, thereby demonstrating that it is a novel promising therapeutic agent for autoimmune diseases.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00091644
Contributor : Annick Harel-Bellan <>
Submitted on : Wednesday, September 6, 2006 - 6:25:14 PM
Last modification on : Thursday, January 11, 2018 - 6:20:36 AM

Links full text

Identifiers

Collections

Citation

Pierre Bobé, Danielle Bonardelle, Karim Benihoud, Paule Opolon, Mounira Chelbi-Alix. Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.. Blood, American Society of Hematology, 2006, 108 (13), pp.3967-75. ⟨10.1182/blood-2006-04-020610⟩. ⟨inserm-00091644⟩

Share

Metrics

Record views

917